ViewRay (ViewRay) Cash And Cash Equivalents : $81.3 Mil (As of Mar. 2023)

View and export this data going back to 2014. Start your Free Trial

What is ViewRay Cash And Cash Equivalents?

ViewRay's quarterly cash and cash equivalents declined from Sep. 2022 ($142.28 Mil) to Dec. 2022 ($135.96 Mil) but then stayed the same from Dec. 2022 ($135.96 Mil) to Mar. 2023 ($81.29 Mil).

ViewRay's annual cash and cash equivalents increased from Dec. 2020 ($156.72 Mil) to Dec. 2021 ($218.35 Mil) but then declined from Dec. 2021 ($218.35 Mil) to Dec. 2022 ($135.96 Mil).

ViewRay Cash And Cash Equivalents Historical Data

The historical data trend for ViewRay's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViewRay Cash And Cash Equivalents Chart

ViewRay Annual Data

Trend

Nov13

Nov14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

167.43

226.78

156.72

218.35

135.96

ViewRay Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash And Cash Equivalents	Get a 7-Day Free Trial															180.06	157.59	142.28	135.96	81.29

ViewRay Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

ViewRay (OTCPK:VRAYQ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

ViewRay Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of ViewRay's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

ViewRay (ViewRay) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViewRay Inc (OTCPK:VRAYQ) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

1099 18th Street, Suite 3000, Denver, CO, USA, 80202

Website

https://www.viewray.com

ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures, and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies. Geographically, it derives a majority of its revenue from the United States.

Executives

Karen Prange	director	1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
B Kristine Johnson	director	366 FERNDALE RD S, WAYZATA MN 55391
Sanket Shah	officer: SVP, General Counsel	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Farhad Fred Ebrahimi	10 percent owner	191 UNIVERSITY BLVD., #246, DENVER CO 80206
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Paul Jr Ziegler	officer: Chief Commercial Officer	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Scott William Drake	director, officer: President and CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Adam Andrew Podbelski	officer: SVP, Customer Services	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Jacob Edward Signoriello	officer: Chief Financial Officer	C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER CO 80202
James F. Dempsey	director, officer: Chief Scientific Officer	C/O VIEWRAY INCORPORATED, 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Burke William P. Mr.	officer: Chief Financial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Susan C Schnabel	director	C/O CREDIT SUISSE FIRST BOSTON, 11 MADISON AVE, NEW YORK NY 10010
Brian K Roberts	director	DIGITAS INC.,, 800 BOYLSTON STREET, BOSTON MA 02199
Zachary William Stassen	officer: Chief Financial Officer	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Daniel Jeffrey Moore	director	100 CYBERONICS BVLD, HOUSTON TX 77058